JPRN-UMIN000036224招募中2 期
Safety and efficacy of Palbociclib in combination with endocrine therapy in ER-positive HER2-negative advanced breast cancer-multi-institutional retrospective study -KBCOG-14 - Safety and efficacy of Palbociclib in combination with endocrine therapy in ER-positive HER2-negative advanced breast cancer- KBCOG-14
Kobe Breast Cancer Oncology Group0 个研究点目标入组 200 人开始时间: 2019年3月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •treated by Palbociclib with endocrine therapy for less than 1 week
研究者
相似试验
进行中（未招募）
1 期
A study for patients with metastatic breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-003170-27-IEGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)550
进行中（未招募）
1 期
A study for patients with advanced breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.EUCTR2013-003170-27-LVGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)601
进行中（未招募）
1 期
A study for patients with metastatic breast cancer (hormone receptor-positive, negative HER2 and resistance to aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior aromatase inhibitors therapy.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-003170-27-ATGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)596
进行中（未招募）
1 期
A study for patients with advanced breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.MedDRA version: 16.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-003170-27-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)601
进行中（未招募）
1 期
A study for patients with advanced breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.EUCTR2013-003170-27-HUGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)348